AlphaQuest LLC Buys 66,169 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

AlphaQuest LLC increased its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 103.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 130,106 shares of the biopharmaceutical company’s stock after purchasing an additional 66,169 shares during the quarter. AlphaQuest LLC’s holdings in Catalyst Pharmaceuticals were worth $3,037,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Federated Hermes Inc. increased its holdings in Catalyst Pharmaceuticals by 52.8% during the third quarter. Federated Hermes Inc. now owns 389,289 shares of the biopharmaceutical company’s stock valued at $7,669,000 after buying an additional 134,509 shares during the period. Y Intercept Hong Kong Ltd lifted its holdings in shares of Catalyst Pharmaceuticals by 1,216.5% during the third quarter. Y Intercept Hong Kong Ltd now owns 165,496 shares of the biopharmaceutical company’s stock worth $3,260,000 after purchasing an additional 152,925 shares during the period. Public Sector Pension Investment Board lifted its holdings in shares of Catalyst Pharmaceuticals by 10.8% during the third quarter. Public Sector Pension Investment Board now owns 516,745 shares of the biopharmaceutical company’s stock worth $10,180,000 after purchasing an additional 50,343 shares during the period. American Century Companies Inc. lifted its holdings in Catalyst Pharmaceuticals by 43.8% in the third quarter. American Century Companies Inc. now owns 2,528,186 shares of the biopharmaceutical company’s stock valued at $49,805,000 after acquiring an additional 770,198 shares during the period. Finally, Rafferty Asset Management LLC lifted its holdings in Catalyst Pharmaceuticals by 64.1% in the third quarter. Rafferty Asset Management LLC now owns 157,044 shares of the biopharmaceutical company’s stock valued at $3,094,000 after acquiring an additional 61,328 shares during the period. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $31.26 on Tuesday. Catalyst Pharmaceuticals, Inc. has a twelve month low of $19.05 and a twelve month high of $32.56. The stock has a 50 day moving average of $26.97 and a two-hundred day moving average of $24.78. The stock has a market capitalization of $3.83 billion, a price-to-earnings ratio of 17.97, a PEG ratio of 0.91 and a beta of 0.72.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Zacks Research cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Citigroup downgraded Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $35.00 to $31.50 in a report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.17.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).